IPASS: DATA FROM AN ONGOING STUDY OF THE TOLERABILITY AND EFFECTIVENESS OF INJECTABLE TESTOSTERONE UNDECANOATE FOR THE TREATMENT OF MALE HYPOGONADISM

被引：0
|
作者：
Zitzmann, M. [1 ]
Hanisch, J. U. [2 ]
Mattern, A. [3 ]
机构：
[1] Univ Clin Munster, Ctr Reprod Med & Androl, Munster, Germany
[2] Bayer Vital GmbH, Leverkusen, Germany
[3] Bayer Schering Pharma AG, Berlin, Germany
来源：
JOURNAL OF SEXUAL MEDICINE | 2010年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：97 / 97
页数：1
相关论文
共 50 条
  • [21] Retrospective Investigation of Testosterone Undecanoate Depot for the Long-term Treatment of Male Hypogonadism in Clinical Practice
    Conaglen, Helen M.
    Paul, Ryan G.
    Yarndley, Tania
    Kamp, Jozef
    Elston, Marianne S.
    Conaglen, John V.
    JOURNAL OF SEXUAL MEDICINE, 2014, 11 (02): : 574 - 582
  • [22] PROSTATE SAFETY OF TESTOSTERONE REPLACEMENT THERAPY IN MALE HYPOGONADISM: INTERIM RESULTS FROM THE LARGEST INTERNATIONAL TRIAL ON INJECTABLE LONG-ACTING TESTOSTERONE UNDECANOATE INVOLVING 763 PATIENTS
    Zitzmann, M.
    Hanisch, J. U.
    Mattern, A.
    Jungwirth, A.
    Maagi, M.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 56 - 57
  • [23] Long-term testosterone undecanoate treatment in the elderly testosterone deficient male: An observational cohort study
    Abildgaard, Julie
    Petersen, Jorgen Holm
    Bang, Anne Kirstine
    Aksglaede, Lise
    Christiansen, Peter
    Juul, Anders
    Jorgensen, Niels
    ANDROLOGY, 2022, 10 (02) : 322 - 332
  • [24] The efficacy and safety of long-acting injectable testosterone undecanoate (Nebido) in late onset hypogonadism patients: A Korean multicenter prospective study
    Moon, D. G.
    Park, J. K.
    Park, K. S.
    Kim, S. W.
    Park, N. C.
    Paik, J. S.
    Seo, J. T.
    Ahn, T. Y.
    Yang, D. Y.
    Lee, S. W.
    Kim, J. J.
    JOURNAL OF SEXUAL MEDICINE, 2008, 5 : 125 - 125
  • [25] Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study
    Haider, Karim Sultan
    Haider, Ahmad
    Saad, Farid
    Doros, Gheorghe
    Hanefeld, Markolf
    Dhindsa, Sandeep
    Dandona, Paresh
    Traish, Abdulmaged
    DIABETES OBESITY & METABOLISM, 2020, 22 (11): : 2055 - 2068
  • [26] Long-Term Treatment with Injectable Testosterone Undecanoate (TU) Improves Lipid Profile in Men with Hypogonadism and Type 2 Diabetes in Comparison to an Untreated Control Group: Ten-Year Data from a Urological Registry Study
    Saad, Farid
    Haider, Karim S.
    Haider, Ahmad
    DIABETES, 2019, 68
  • [27] Effectiveness and tolerability of parenteral testosterone undecanoate: a post-marketing surveillance study (vol 20, pg 225, 2017)
    J, Wolf
    Keipert, D.
    Motazedi, H.
    Gooren, Louis
    AGING MALE, 2017, 20 (04): : I - I
  • [28] Sustained Weight Loss in Men with Hypogonadism and Type 2 Diabetes (T2DM) Receiving Long-Term Treatment with Injectable Testosterone Undecanoate (TU): Ten-Year Data from a Urological Registry Study
    Haider, Ahmad
    Haider, Karim S.
    Saad, Farid
    DIABETES, 2019, 68
  • [29] Beneficial Changes in Glycemic Control in Patients with Hypogonadism and Type 2 Diabetes (T2DM) Receiving Long-Term Treatment with Injectable Testosterone Undecanoate (TU): Ten-Year Data from a Registry
    Saad, Farid
    Haider, Karim S.
    Haider, Ahmad
    DIABETES, 2019, 68
  • [30] PERCUTANEOUS ANDROGEN TREATMENT OF MALE HYPOGONADISM - COMPARISON OF THE EFFICACY OF TESTOSTERONE AND DIHYDROTESTOSTERONE - A STUDY OF 40 CASES
    KUHN, JM
    LAUDAT, MH
    DELIGNIERES, B
    BRICAIRE, H
    LUTON, JP
    CONTRACEPTION FERTILITE SEXUALITE, 1986, 14 (11): : 1031 - 1036
12345